Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Experiences Heavier than Usual Trading Volume

Postado Julho 17, 2017

Stock research firms now have a positive stance on shares of Golden Minerals Company (:AUMN). FIL Ltd owned 0.44% of Zimmer Biomet Holdings worth $108,066,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 84.17% of the company's stock. Thrivent Financial for Lutherans raised its stake in shares of Zimmer Biomet Holdings by 6.7% in the fourth quarter. The firm has "Strong Buy" rating by Needham given on Friday, April 28. Raymond James Trust N.A. increased its position in Zimmer Biomet Holdings by 0.3% in the first quarter. BlackRock Inc. now owns 16,740,383 shares of the medical equipment provider's stock worth $2,044,168,000 after buying an additional 16,336,262 shares during the last quarter. Levin Capital Strategies L.P. raised its stake in shares of Zimmer Biomet Holdings by 41.9% in the fourth quarter. The legal version of this story can be accessed at https://sportsperspectives.com/2017/07/16/oppenheimerfunds-inc-lowers-position-in-zimmer-biomet-holdings-inc-zbh-updated-updated.html. Also, insider Sang Yi sold 17,731 shares of Zimmer Biomet Holdings stock in a transaction on Monday, June 12th.

Shares of Zimmer Biomet Holdings (NYSE:ZBH) opened at 132.49 on Friday. The stock has a market cap of $26.72 billion, a PE ratio of 54.23 and a beta of 1.21. The company's 50-day moving average is $123.43 and its 200-day moving average is $117.75.

Zimmer Biomet Holdings (NYSE:ZBH) last issued its quarterly earnings data on Thursday, April 27th. First Republic Investment Management Inc. now owns 31,630 shares of the medical equipment provider's stock worth $3,264,000 after buying an additional 2,140 shares in the last quarter. Zimmer Biomet Holdings had a net margin of 6.36% and a return on equity of 16.80%. The business had revenue of $1.98 billion during the quarter, compared to the consensus estimate of $1.96 billion.

Zimmer Biomet Holdings, Inc. has a 1-year low of $95.63 and a 1-year high of $133.21. Zimmer Biomet Holdings's revenue was up 3.8% compared to the same quarter previous year.

COPYRIGHT VIOLATION NOTICE: "Zimmer Biomet Holdings, Inc". A value of 0 would indicate that shares are now trading at the 52-week low. This dividend represents a yeild of $0.72 which is the dividend as a percentage of the current share price. The ex-dividend date has been established as Wednesday the 21st of June 2017. Zimmer Biomet Holdings's payout ratio is now 39.67%. "(ZBH) Shares Bought by North Star Asset Management Inc." was originally published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this news story on another domain, it was stolen and republished in violation of USA and worldwide trademark & copyright law.

Several equities analysts have weighed in on the company. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Finally, Wells Fargo & Company reissued a "market weight" rating on shares of Zimmer Biomet Holdings in a research note on Friday. The stock of Zimmer Biomet Holdings Inc (NYSE:ZBH) earned "Buy" rating by Guggenheim on Wednesday, July 12. August 23 investment analysts at Barclays made no change to the stock rating of "Overweight" and raised the price target to $145.00 from $140.00. UBS downgraded the shares of ZBH in report on Thursday, December 15 to "Sell" rating. The company has a consensus rating of "Buy" and a consensus price target of $138.95. The shares were sold at an average price of $124.56, for a total value of $2,208,573.36. The sale was disclosed in a filing with the SEC, which is available through this link.

In other news, VP Chad F. Phipps sold 6,200 shares of the company's stock in a transaction dated Friday, May 5th. The shares were sold at an average price of $116.47, for a total value of $10,171,441.57. The disclosure for this sale can be found here.

Zimmer Biomet Holdings, Inc., launched on January 12, 2001, is involved in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.